IL-37 links ACLY-centered lipid metabolic reprogramming to myeloid immunosuppression in pancreatic ductal adenocarcinoma
International Immunopharmacology · 2026-12 · 191 · 117589
DOI: 10.1016/j.intimp.2026.117589 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Ziwei Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study investigated the role of IL-37 in PDAC and its association with lipid metabolic reprogramming and tumour immune suppression. Bioinformatic analyses, paired clinical specimens, IL-37 gain- and loss-of-function models, and in vitro and in vivo functional assays were used to characterize the role of IL-37 in PDAC. Tumour immune profiles and metabolic alterations were assessed by flow cytometry, immunofluorescence, molecular analyses, and untargeted metabolomics. Bone marrow-derived MDSC assays and pharmacological AKT inhibition were used for mechanistic validation, and the effects of ACLY inhibition and Gr-1 blockade were further evaluated in vivo. IL-37 was upregulated in PDAC tissues and cell lines and was associated with shorter overall survival. IL-37 overexpression enhanced cell viability, clonogenicity, migration, invasion, and tumour growth, whereas IL-37 knockdown produced the opposite effects. IL-37 overexpression was also associated with increased CD11b+Gr-1+ myeloid-derived suppressor cell accumulation and impaired CD8+ T-cell infiltration. Tumour-derived IL-37-associated signals further promoted MDSC generation and preferentially shifted the population toward M-MDSCs in vitro. Metabolomic and molecular analyses revealed an ACLY-centred lipid metabolic programme involving increased ACLY, FASN, and SPHK1 expression and alterations in acetyl-CoA, palmitate, and sphingosine-1-phosphate. IL-37 enhanced AKT phosphorylation, whereas AKT inhibition attenuated the upregulation of ACLY, FASN, and SPHK1, supporting a functional role for AKT signalling in this metabolic phenotype. ACLY inhibition, particularly in combination with Gr-1 blockade, reduced lipid accumulation and myeloid-cell infiltration, restored CD8+ T-cell responses, and suppressed tumour growth. IL-37 promotes PDAC progression in association with AKT-related signalling, ACLY-centred lipid metabolic reprogramming and an immunosuppressive tumour microenvironment. Combined targeting of lipid metabolism and immunosuppressive myeloid cells may represent a therapeutic strategy for IL-37-high PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Hospital of Jilin University, Changchun, Jilin, China.
- Basic College of Medicine, Jilin Medical University, Jilin, China.
- State Key Laboratory of Pathogen and Biosecurity, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, China.
- The Second Hospital of Jilin University, Changchun, Jilin, China. Electronic address: linrx@jlu.edu.cn.
Zitieren
APA
Liu, Z., Sun, G., Xu, N., Chen, Y., Dong, M., Geng, X., Chen, B., Liu, W., & Lin, R. (2026). IL-37 links ACLY-centered lipid metabolic reprogramming to myeloid immunosuppression in pancreatic ductal adenocarcinoma. International Immunopharmacology, 191, 117589. https://doi.org/10.1016/j.intimp.2026.117589
Vancouver
Liu Z, Sun G, Xu N, Chen Y, Dong M, Geng X, et al. IL-37 links ACLY-centered lipid metabolic reprogramming to myeloid immunosuppression in pancreatic ductal adenocarcinoma. International Immunopharmacology. 2026;191:117589. doi:10.1016/j.intimp.2026.117589
BibTeX
@article{Liu2026,
author = {Liu, Ziwei and Sun, Guangchao and Xu, Na and Chen, Yuying and Dong, Mingxin and Geng, Xiao and Chen, Baichuan and Liu, Wensen and Lin, Ruixin},
title = {IL-37 links ACLY-centered lipid metabolic reprogramming to myeloid immunosuppression in pancreatic ductal adenocarcinoma},
journal = {International Immunopharmacology},
year = {2026},
volume = {191},
pages = {117589},
doi = {10.1016/j.intimp.2026.117589}
}
EUVIMED